Effect of CpG motif containing oligodeoxynucleotides on dendritic cell function in patients with chronic hepatitis B.
OBJECTIVE
To explore the effect of unmethylated CpG motif containing oligodeoxynucleotides (CpG ODN) on the function of dendritic cells (DCs) in patients with chronic hepatitis B (CHB).


METHODS
DCs were obtained from peripheral blood mononuclear cells (PBMCs) of 15 CHB patients, 12 hepatitis B virus (HBV) carriers, and 10 healthy controls. The expressions of HLA-DR, CD80, and CD86 on DCs were determined by fluorescence activated cell sorting (FACS). The IL-12 level in supernatant of the culture medium was measured by ELISA, and the morphological changes of DCs were observed under transmission electron microscope.


RESULTS
Compared with the controls, DCs stimulated with CpG ODN represented enrichment in cell surface protrusions and rough endoplasmic reticulum, decreased or disappeared vacuole. The expressions of HLA-DR, CD86, and CD80 were much higher in DCs stimulated with CpG ODN than those in complete medium control (P<0.05). When culturing in complete medium, the expressions of HLA-DR, CD86, and CD80 were much lower in CHB patients and HBV carriers than healthy controls (P<0.05). The expressions of HLA-DR and CD86 stimulated with CpG ODN were much lower in CHB patients than HBV carriers and healthy controls (P<0.05). The expressions of CD80 were much lower in CHB patients and HBV carriers than healthy controls (P<0.05). The levels of IL-12 were much higher in DCs stimulated with CpG ODN than that in complete medium controls (P<0.05). The levels of IL-12 in complete medium or medium added with CpG ODN were much lower in CHB patients and HBV carriers than in healthy controls (P<0.05).


CONCLUSIONS
CpG ODN could significantly promote the maturation of dendritic cells in peripheral blood in CHB patients.
You
Yunhui
Y
Department of Rheumatology, Xiangya Hospital, Central South University, Changsha 410008, China.
Fan
Xuegong
X
Huang
Zhenyu
Z
Li
Ning
N
D000328:Adult; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen / Q000378:metabolism; D002353:Carrier State / Q000276:immunology; D016022:Case-Control Studies; D018899:CpG Islands; D003713:Dendritic Cells / Q000187:drug effects* / Q000276:immunology*; D005260:Female; D006684:HLA-DR Antigens / Q000378:metabolism; D019694:Hepatitis B, Chronic / Q000276:immunology*; D006801:Humans; D008297:Male; D009838:Oligodeoxyribonucleotides / Q000494:pharmacology*
D018122:B7-1 Antigen; D051940:B7-2 Antigen; C408982:CPG-oligonucleotide; D006684:HLA-DR Antigens; D009838:Oligodeoxyribonucleotides